Urologic Oncology: Seminars and Original Investigations - Estadísticas de Google Académico

Índice h5:44
Mediana h5:59

El índice h5 es el índice h de los artículos publicados en los últimos 5 años completos. Se trata del número mayor h en cuanto a que h artículos publicados entre 2014 - 2018 deben tener al menos h citas cada uno.ocultar

La mediana h5 de una publicación es el número mediano de citas de los artículos que componen el índice h5.ocultar

#13 Urology & Nephrology

Título / Autor	Citado por	Año
Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: A randomized study V Panebianco, F Barchetti, A Sciarra, A Ciardi, EL Indino, R Papalia, ... Urologic Oncology: Seminars and Original Investigations 33 (1), 17. e1-17. e7	173	2015
Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance AW Diaz, NA Shakir, AK George, S Rais-Bahrami, B Turkbey, JT Rothwax, ... Urologic Oncology: Seminars and Original Investigations 33 (5), 202. e1-202. e7	124	2015
The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—Can it rule out clinically significant prostate cancer? M Abd-Alazeez, HU Ahmed, M Arya, SC Charman, E Anastasiadis, ... Urologic Oncology: Seminars and Original Investigations 32 (1), 45. e17-45. e22	113	2014
The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research BT Ristau, DS O'Keefe, DJ Bacich Urologic Oncology: Seminars and Original Investigations 32 (3), 272-279	104	2014
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer FA Yafi, F Brimo, J Steinberg, AG Aprikian, S Tanguay, W Kassouf Urologic Oncology: Seminars and Original Investigations 33 (2), 66. e25-66. e31	98	2015
Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer M Fraser, A Berlin, RG Bristow, T van der Kwast Urologic Oncology: Seminars and Original Investigations 33 (2), 85-94	88	2015
Target detection: Magnetic resonance imaging-ultrasound fusion–guided prostate biopsy GA Sonn, DJ Margolis, LS Marks Urologic Oncology: Seminars and Original Investigations 32 (6), 903-911	87	2014
Urine microRNAs as potential noninvasive biomarkers in urologic cancers H Mlcochova, R Hezova, M Stanik, O Slaby Urologic Oncology: Seminars and Original Investigations 32 (1), 41. e1-41. e9	87	2014
Urine markers for detection and surveillance of bladder cancer E Xylinas, LA Kluth, M Rieken, PI Karakiewicz, Y Lotan, SF Shariat Urologic Oncology: Seminars and Original Investigations 32 (3), 222-229	80	2014
Changes in epidemiologic features of testicular germ cell cancer: Age at diagnosis and relative frequency of seminoma are constantly and significantly increasing CG Ruf, H Isbarn, W Wagner, M Fisch, C Matthies, KP Dieckmann Urologic Oncology: Seminars and Original Investigations 32 (1), 33. e1-33. e6	78	2014
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature GA Bjarnason, B Khalil, JM Hudson, R Williams, LM Milot, M Atri, A Kiss, ... Urologic Oncology: Seminars and Original Investigations 32 (4), 480-487	75	2014
Prostate cancer biomarkers: An update JR Otero, BG Gomez, FC Juanatey, KA Touijer Urologic Oncology: Seminars and Original Investigations 32 (3), 252-260	72	2014
Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non–muscle-invasive bladder cancer R Mano, J Baniel, O Shoshany, D Margel, T Bar-On, O Nativ, J Rubinstein, ... Urologic Oncology: Seminars and Original Investigations 33 (2), 67. e1-67. e7	71	2015
The evolving understanding of microRNA in bladder cancer EA Guancial, J Bellmunt, S Yeh, JE Rosenberg, DM Berman Urologic Oncology: Seminars and Original Investigations 32 (1), 41. e31-41. e40	69	2014
Primary care physician PSA screening practices before and after the final US Preventive Services Task Force recommendation JA Cohn, CE Wang, JC Lakeman, JC Silverstein, CB Brendler, ... Urologic Oncology: Seminars and Original Investigations 32 (1), 41. e23-41. e30	68	2014
Utility of [11C] choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: Results from a pathologically validated series NM Passoni, N Suardi, F Abdollah, M Picchio, G Giovacchini, C Messa, ... Urologic Oncology: Seminars and Original Investigations 32 (1), 38. e9-38. e16	63	2014
Can we expand active surveillance criteria to include biopsy Gleason 3+ 4 prostate cancer? A multi-institutional study of 2,323 patients G Ploussard, H Isbarn, A Briganti, P Sooriakumaran, CI Surcel, L Salomon, ... Urologic Oncology: Seminars and Original Investigations 33 (2), 71. e1-71. e9	61	2015
Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy RT Gupta, KF Faridi, AA Singh, NM Passoni, K Garcia-Reyes, JF Madden, ... Urologic Oncology: Seminars and Original Investigations 32 (8), 1292-1299	60	2014
Natural history of surgically treated high-risk prostate cancer A Briganti, RJ Karnes, G Gandaglia, M Spahn, P Gontero, L Tosco, ... Urologic Oncology: Seminars and Original Investigations 33 (4), 163. e7-163. e13	60	2015
Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis AP Mitra, CC Bartsch, G Bartsch Jr, G Miranda, EC Skinner, ... Urologic Oncology: Seminars and Original Investigations 32 (2), 117-127	59	2014

1 - 20

Las fechas y los recuentos de citas son estimados y se determinan de forma automática mediante un programa informático.